source
- FDA approves Roche's Wilserdly for advanced HR-positive, HER2-negative breast cancer with ESR1 mutationThe U.S. Food and Drug Administration has granted approval to Roche's new oral breast cancer therapy, Wilserdly (giredestrant). The decision clears the way for the drug's launch in the United State…
- CG Oncology’s cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 trialCG Oncology reported that its experimental therapy, cretostimogene, achieved a 68% relative reduction in bladder cancer recurrence in a Phase 3 study of patients who had surgery for non‑muscle inva…